Ahmed Gabr1, Joseph Ralph Kallini1, Vanessa L Gates1, Ryan Hickey1, Laura Kulik2, Kush Desai1, Bartley Thornburg1, Karen Marshall1, Krystina Salzig1, Melissa Williams1, Carlene Del Castillo1, Daniel Ganger2, Elias Hohlastos1, Talia Baker3, Robert J Lewandowski1, Riad Salem4,5,6. 1. Department of Radiology, Section of Interventional Radiology, Northwestern Memorial Hospital, Robert H. Lurie Comprehensive Cancer Center, 676 N. St. Clair, Suite 800, Chicago, IL, 60611, USA. 2. Department of Medicine, Division of Hepatology, Northwestern University, Chicago, IL, USA. 3. Department of Surgery, Division of Transplantation, Comprehensive Transplant Center, Northwestern University, Chicago, IL, USA. 4. Department of Radiology, Section of Interventional Radiology, Northwestern Memorial Hospital, Robert H. Lurie Comprehensive Cancer Center, 676 N. St. Clair, Suite 800, Chicago, IL, 60611, USA. r-salem@northwestern.edu. 5. Department of Surgery, Division of Transplantation, Comprehensive Transplant Center, Northwestern University, Chicago, IL, USA. r-salem@northwestern.edu. 6. Department of Medicine, Division of Hematology and Oncology, Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL, USA. r-salem@northwestern.edu.
Abstract
PURPOSE: To assess the feasibility of conducting pretreatment mesenteric angiography, coil embolization, 99mTc macroaggregated albumin (99mTc-MAA) scintigraphy, and 90Y radioembolization treatment in a single, same-day, combined outpatient encounter. METHODS: This was a retrospective study of 78 patients treated during the period 2008 - 2015 who were managed in a single outpatient encounter under the guidance of the Interventional Radiology Department and The Nuclear Medicine Department. Pretreatment planning was performed by reviewing baseline imaging and estimated perfused liver volume bearing the tumor. The region of interest was estimated using 3-D software; this value was used for dosimetry planning. Maximum lung shunting fractions of 10 % for hepatocellular carcinoma and 5 % for liver metastases were assumed. Subsequently, hepatic angiography and 99mTc-MAA scintigraphy were performed followed by 90Y treatment in one outpatient encounter. Total in-room procedure time was recorded. RESULTS: All patients underwent same-day angiography, 99mTc-MAA scintigraphy and 90Y radioembolization. Of the 78 patients, 16 received multiple segmental treatments to both lobes, 44 received treatment to the right lobe, and 18 received treatment to the left lobe. The median dose was 106 Gy. The median number of 90Y vials needed was two (range one to six). The median in-room time was 160 min (75 - 250 min). The residential status of the patients was as follows, 18 % (14/78) were local residents, 55 % (43/78) traveled from outside the city limits, 18 % (14/78) were from out-of-state, and 9 % (7/78) were resident abroad. Of the 78 patients, 61 (77 %) had hepatocellular carcinoma, and 17 (22 %) had liver metastases. The median lung dose was 3.5 Gy. CONCLUSION: This study demonstrated the feasibility of same-day 90Y evaluation and treatment while maintaining the principles of safe and effective 90Y infusion including tumoricidal dosimetry (lobar, segmentectomy), minimization of nontarget flow, and minimization of lung dose. This paradigm translates into expeditious cancer care and significant cost savings.
PURPOSE: To assess the feasibility of conducting pretreatment mesenteric angiography, coil embolization, 99mTc macroaggregated albumin (99mTc-MAA) scintigraphy, and 90Y radioembolization treatment in a single, same-day, combined outpatient encounter. METHODS: This was a retrospective study of 78 patients treated during the period 2008 - 2015 who were managed in a single outpatient encounter under the guidance of the Interventional Radiology Department and The Nuclear Medicine Department. Pretreatment planning was performed by reviewing baseline imaging and estimated perfused liver volume bearing the tumor. The region of interest was estimated using 3-D software; this value was used for dosimetry planning. Maximum lung shunting fractions of 10 % for hepatocellular carcinoma and 5 % for liver metastases were assumed. Subsequently, hepatic angiography and 99mTc-MAA scintigraphy were performed followed by 90Y treatment in one outpatient encounter. Total in-room procedure time was recorded. RESULTS: All patients underwent same-day angiography, 99mTc-MAA scintigraphy and 90Y radioembolization. Of the 78 patients, 16 received multiple segmental treatments to both lobes, 44 received treatment to the right lobe, and 18 received treatment to the left lobe. The median dose was 106 Gy. The median number of 90Y vials needed was two (range one to six). The median in-room time was 160 min (75 - 250 min). The residential status of the patients was as follows, 18 % (14/78) were local residents, 55 % (43/78) traveled from outside the city limits, 18 % (14/78) were from out-of-state, and 9 % (7/78) were resident abroad. Of the 78 patients, 61 (77 %) had hepatocellular carcinoma, and 17 (22 %) had liver metastases. The median lung dose was 3.5 Gy. CONCLUSION: This study demonstrated the feasibility of same-day 90Y evaluation and treatment while maintaining the principles of safe and effective 90Y infusion including tumoricidal dosimetry (lobar, segmentectomy), minimization of nontarget flow, and minimization of lung dose. This paradigm translates into expeditious cancer care and significant cost savings.
Authors: William A Dezarn; Jeffery T Cessna; Larry A DeWerd; Wenzheng Feng; Vanessa L Gates; James Halama; Andrew S Kennedy; Subir Nag; Mehrdad Sarfaraz; Varun Sehgal; Reed Selwyn; Michael G Stabin; Bruce R Thomadsen; Lawrence E Williams; Riad Salem Journal: Med Phys Date: 2011-08 Impact factor: 4.071
Authors: T W Leung; W Y Lau; S K Ho; S C Ward; J H Chow; M S Chan; C Metreweli; P J Johnson; A K Li Journal: Int J Radiat Oncol Biol Phys Date: 1995-11-01 Impact factor: 7.038
Authors: Monia E Hamami; Thorsten D Poeppel; Stephan Müller; Till Heusner; Andreas Bockisch; Philipp Hilgard; Gerald Antoch Journal: J Nucl Med Date: 2009-04-16 Impact factor: 10.057
Authors: John D Louie; Nishita Kothary; William T Kuo; Gloria L Hwang; Lawrence V Hofmann; Michael L Goris; Andrei H Iagaru; Daniel Y Sze Journal: J Vasc Interv Radiol Date: 2009-04-05 Impact factor: 3.464
Authors: Michael Vouche; Ali Habib; Thomas J Ward; Edward Kim; Laura Kulik; Daniel Ganger; Mary Mulcahy; Talia Baker; Michael Abecassis; Kent T Sato; Juan-Carlos Caicedo; Jonathan Fryer; Ryan Hickey; Elias Hohlastos; Robert J Lewandowski; Riad Salem Journal: Hepatology Date: 2014-05-27 Impact factor: 17.425
Authors: Riad Salem; Siddharth A Padia; Marnix Lam; Carlo Chiesa; Paul Haste; Bruno Sangro; Beau Toskich; Kirk Fowers; Joseph M Herman; S Cheenu Kappadath; Thomas Leung; Daniel Y Sze; Edward Kim; Etienne Garin Journal: Eur J Nucl Med Mol Imaging Date: 2022-09-17 Impact factor: 10.057
Authors: Adam Swersky; Laura Kulik; Aparna Kalyan; Karen Grace; Juan Carlos Caicedo; Robert J Lewandowski; Riad Salem Journal: Semin Intervent Radiol Date: 2021-10-07 Impact factor: 1.780
Authors: Riad Salem; Andrew C Gordon; Samdeep Mouli; Ryan Hickey; Joseph Kallini; Ahmed Gabr; Mary F Mulcahy; Talia Baker; Michael Abecassis; Frank H Miller; Vahid Yaghmai; Kent Sato; Kush Desai; Bartley Thornburg; Al B Benson; Alfred Rademaker; Daniel Ganger; Laura Kulik; Robert J Lewandowski Journal: Gastroenterology Date: 2016-08-27 Impact factor: 22.682
Authors: Mohammad Elsayed; Mohammad Loya; James Galt; David M Schuster; Zachary L Bercu; Janice Newsome; David Brandon; Sonia Benenati; Keywan Behbahani; Richard Duszak; Ila Sethi; Nima Kokabi Journal: World J Gastrointest Oncol Date: 2021-05-15